Literature DB >> 26057061

Nuclear imaging of renal tumours: a step towards improved risk stratification.

Michael A Gorin1, Steven P Rowe2, Mohamad E Allaf1.   

Abstract

Patients presenting with a clinically localized renal mass should ideally be managed with a risk-adapted approach that incorporates data regarding the metastatic potential of a given tumour. Unfortunately, currently available anatomical imaging techniques are unable to reliably distinguish between the various types of renal tumours, which include both benign and malignant histologies. Nuclear imaging offers a potential noninvasive means to characterize clinically localized renal tumours. A number of nuclear imaging tests are currently under investigation for this purpose and might one day be incorporated into patient care.

Entities:  

Mesh：

Year:  2015        PMID： 26057061     DOI： 10.1038/nrurol.2015.122

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  48 in total

Review 1.  New aspects of the Warburg effect in cancer cell biology.

Authors:  Steven J Bensinger; Heather R Christofk
Journal:  Semin Cell Dev Biol       Date:  2012-03-08       Impact factor: 7.727

2.  The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.

Authors:  John R Srigley; Brett Delahunt; John N Eble; Lars Egevad; Jonathan I Epstein; David Grignon; Ondrej Hes; Holger Moch; Rodolfo Montironi; Satish K Tickoo; Ming Zhou; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

Review 3.  Solid renal masses: what the numbers tell us.

Authors:  Stella K Kang; William C Huang; Pari V Pandharipande; Hersh Chandarana
Journal:  AJR Am J Roentgenol       Date:  2014-06       Impact factor: 3.959

Review 4.  Role of percutaneous needle biopsy for renal masses.

Authors:  Elaine M Caoili; Matthew S Davenport
Journal:  Semin Intervent Radiol       Date:  2014-03       Impact factor: 1.513

5.  (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

Authors:  Emre Demirci; Meltem Ocak; Levent Kabasakal; Clemens Decristoforo; Zübeyir Talat; Metin Halaç; Bedii Kanmaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-23       Impact factor: 9.236

6.  Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts.

Authors:  P A Carvalho; M L Chiu; J F Kronauge; M Kawamura; A G Jones; B L Holman; D Piwnica-Worms
Journal:  J Nucl Med       Date:  1992-08       Impact factor: 10.057

7.  A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.

Authors:  Tamer Ozülker; Filiz Ozülker; Emin Ozbek; Tevfik Ozpaçaci
Journal:  Nucl Med Commun       Date:  2011-04       Impact factor: 1.690

8.  Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.

Authors:  Angelo Baccala; Linda Sercia; Jianbo Li; Warren Heston; Ming Zhou
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

9.  Grade heterogeneity in small renal masses: potential implications for renal mass biopsy.

Authors:  Mark W Ball; Stephania M Bezerra; Michael A Gorin; Morgan Cowan; Christian P Pavlovich; Phillip M Pierorazio; George J Netto; Mohamad E Allaf
Journal:  J Urol       Date:  2014-06-21       Impact factor: 7.450

Review 10.  Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma.

Authors:  Hsin-Yi Wang; Hueisch-Jy Ding; Jin-Hua Chen; Chih-Hao Chao; Yu-Yu Lu; Wan-Yu Lin; Chia-Hung Kao
Journal:  Cancer Imaging       Date:  2012-10-26       Impact factor: 3.909
View more
  7 in total

1.  Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT.

Authors:  Yafu Yin; Scott P Campbell; Mark C Markowski; Philip M Pierorazio; Martin G Pomper; Mohamad E Allaf; Steven P Rowe; Michael A Gorin
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

Review 2.  Imaging Protocols for Active Surveillance in Renal Cell Carcinoma.

Authors:  Christine W Liaw; Jared S Winoker; Reza Mehrazin
Journal:  Curr Urol Rep       Date:  2018-08-13       Impact factor: 3.092

3.  Computed Tomography Appearance of Renal Hybrid Oncocytic/Chromophobe Tumors.

Authors:  Akrita Bhatnagar; Steven P Rowe; Michael A Gorin; Martin G Pomper; Elliot K Fishman; Mohamad E Allaf
Journal:  J Comput Assist Tomogr       Date:  2016 Jul-Aug       Impact factor: 1.826

4.  Available active surveillance follow-up protocols for small renal mass: a systematic review.

Authors:  Giacomo Rebez; Nicola Pavan; M Carmen Mir
Journal:  World J Urol       Date:  2021-01-16       Impact factor: 4.226

5.  Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality?

Authors:  Steven P Rowe; Mehrbod S Javadi; Mohamad E Allaf; Michael A Gorin
Journal:  EJNMMI Res       Date:  2017-04-12       Impact factor: 3.138

Review 6.  Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX.

Authors:  Joseph Lau; Kuo-Shyan Lin; François Bénard
Journal:  Theranostics       Date:  2017-09-26       Impact factor: 11.556

7.  Correlation of 99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression.

Authors:  Steven P Rowe; Michael A Gorin; Lilja B Solnes; Mark W Ball; Ajuni Choudhary; Phillip M Pierorazio; Jonathan I Epstein; Mehrbod S Javadi; Mohamad E Allaf; Alex S Baras
Journal:  EJNMMI Res       Date:  2017-10-02       Impact factor: 3.138
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.